BioLineRx (NASDAQ:BLRX) Releases Earnings Results, Beats Expectations By $0.07 EPS

BioLineRx (NASDAQ:BLRX) announced its earnings results on Tuesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The company had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same period last year, the firm earned ($0.09) earnings per share.

BioLineRx Trading Up 7.8 %

BioLineRx stock opened at $1.11 on Thursday. The business has a 50 day moving average price of $1.21 and a two-hundred day moving average price of $1.47. The company has a quick ratio of 1.86, a current ratio of 1.96 and a debt-to-equity ratio of 0.64. The stock has a market cap of $80.41 million, a price-to-earnings ratio of -1.32 and a beta of 1.40. BioLineRx has a 12 month low of $0.81 and a 12 month high of $2.53.

Wall Street Analysts Forecast Growth

BLRX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of BioLineRx in a research note on Tuesday. StockNews.com upgraded BioLineRx to a “sell” rating in a research note on Wednesday.

Hedge Funds Weigh In On BioLineRx

Several large investors have recently added to or reduced their stakes in BLRX. Renaissance Technologies LLC raised its holdings in BioLineRx by 278.0% in the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx in the 1st quarter worth approximately $178,000. Envestnet Asset Management Inc. acquired a new position in shares of BioLineRx in the 1st quarter worth approximately $88,000. Finally, LPL Financial LLC raised its holdings in shares of BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares in the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.